Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
BALTIMORE - TNF Pharmaceuticals, Inc. (NASDAQ: TNFA), in collaboration with Renova Health, has revealed positive initial results from a study focusing on patients treated with GLP-1 agonists, such as Wegovy® or Ozempic®. The study, part of a series, evaluates the effects of the company’s novel oral TNF-alpha inhibitor, isomyosamine, on preserving lean muscle mass amid weight loss treatments. With a market capitalization of just $1.95 million and a healthy current ratio of 1.4, InvestingPro data shows the company maintains more cash than debt on its balance sheet.
The first stage of the study analyzed data from 30,000 patients to identify those at risk of inflammation-related chronic disorders. This data will help TNF optimize patient recruitment and expedite the development of isomyosamine. Mitchell Glass, M.D., TNF’s President and Chief Medical Officer, noted the underreporting of conditions like sarcopenia and frailty, indicating that patients could face adverse events from GLP-1 treatments without proper monitoring. According to InvestingPro, investors should note that the company’s next earnings report is scheduled for May 14, 2025, which could provide crucial updates on the study’s progress.
Dave Jacobs, CEO of Renova Health, highlighted the study’s potential to improve early detection and support for at-risk patients through non-invasive monitoring. The aim is to enhance the quality of life for thousands of patients by using validated tests for balance and cognition.
Isomyosamine is a small molecule derived from plant alkaloids, designed to regulate the immune system by modulating inflammatory cytokines, including TNF-alpha. TNF Pharmaceuticals is also developing a second drug platform, Supera-CBD, targeting chronic pain, addiction, and epilepsy.
The company’s press release includes forward-looking statements that are subject to known and unknown risks and uncertainties. These statements reflect the company’s current views and expectations about future events and performance. With a beta of 2.53 and a significant 92.95% decline in share price over the past year, investors should carefully consider the volatility risks. TNF Pharmaceuticals has disclaimed any intention or obligation to update these statements, emphasizing that actual results may differ due to various factors.
The information in this article is based on a press release statement from TNF Pharmaceuticals, Inc.
In other recent news, TNF Pharmaceuticals has implemented artificial intelligence in collaboration with Renova Health to improve patient selection for clinical trials. This initiative aims to enhance the recruitment process for trials involving isomyosamine, a drug intended for muscle mass preservation during GLP-1 treatment. Concurrently, TNF Pharmaceuticals is facing a potential delisting from the Nasdaq Stock Market due to its stock not meeting the minimum required bid price of $1.00 per share. The company has been granted a 180-day period to comply with the listing rules. Additionally, TNF Pharmaceuticals recently held a conference call to discuss advancements in their lead compound, Isomyosamine, with details available in a transcript filed with the SEC. The company continues to focus on transparency and communication with stakeholders regarding its research and development activities. TNF Pharmaceuticals also emphasizes the potential of their partnership with Renova Health to advance precision medicine. The company remains active on The Nasdaq Capital Market while working to resolve its listing compliance issues.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.